Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck Serono Rebif meets primary endpoint in Phase III Reflex 1 study
Reflex study was conducted with the serum-free formulation of Rebif 3, which was first introduced in 2007 and is now available in all EU countries, Australia, Canada and
Reflex study was conducted with the serum-free formulation of Rebif 3, which was first introduced in 2007 and is now available in all EU countries, Australia, Canada and
Specifically, the Teracles study will evaluate whether once daily oral Teriflunomide 14 or 7mg, in patients treated for at least 6 months on a stable dose of IFN
HealthStream has posted a net income of $796,000 for the third quarter 2010, compared to a net income of $1.02m in the third quarter of 2009. HealthStream has
As per the agreement with Cipla, Dr Reddy’s has initiated the sales and promotion of the portfolio of products from Q2 FY11 in select therapy areas in Russia
Rockland is expected to construct vectors of some of the anti-cancer drugs Herceptin, Rituxan, Zevalin and Erbitux to accelerate the development of the generic version of these antibodies.
Enoxaparin, a low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis. The patent entitled, "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles
Glassia is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterised by
AZD9773 is a first in class anti-TNF-alpha polyclonal antibody fragment (Fab) product. The Phase IIb study is a multicentre, randomised, double-blind, placebo controlled trial in 300 patients which
X-Excite is a new formulation of an existing sexual enchancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance, the company said.
The two multi-center, double-blind, randomised, controlled studies showed that RT001 was well tolerated and demonstrated efficacy versus controls. Revance said that the first study enrolled 90 subjects and